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Abstract. A total of 495 Campylobacter jejuni and 122 C. coli isolated from Thai children were
screened for macrolide (erythromycin and azithromycin) resistance by disk diffusion assay.
Minimum inhibitory concentrations for erythromycin, azithromycin, nalidixic acid, ciprofloxacin,
tetracycline, streptomycin, gentamicin and chloramphenicol were further determined for these
macrolide-resistant Campylobacter isolates. Presence of known point mutations resulting in
reduced susceptibility to macrolides was investigated by PCR and DNA sequencing. Seven-
teen percent (23/122) of C. coli and 2.4% (12/495) of C. jejuni isolates were resistant to
macrolides. By sequencing domain V of the 23S ribosomal DNA from all 35 macrolide-resis-
tant isolates, a known point mutation of 23S rRNA associated with reduced susceptibility to
macrolides was detected in all isolates except one. Among the macrolide-resistant isolates, all
were multiply resistant to nalidixic acid and ciprofloxacin, of which the latter is the preferred
antimicrobial used for diarrheal treatment in Thailand. Furthermore, most macrolide-resistant
isolates were also resistant to tetracycline and streptomycin. The spread of macrolide and
quinolone resistant Campylobacter should be monitored closely in Thailand and elsewhere as
these antimicrobials are preferred drugs for treatment of diarrhea.
increased and multiple resistant isolates have
emerged as a public health problem. In Thai-
land, fluoroquinolones have previously been
used for treatment of diarrhea and high level
fluoroquinolone resistance has led to increased
use of macrolides, eg erythromycin or azithro-
mycin, for treatment of campylobacteriosis
(Murphy et al, 1996; Hoge et al, 1998). Any
emergence and spread of multiple resistant
Campylobacter spp is of great concern and
should be monitored closely.
There exist several mechanisms resulting
in reduced susceptibility to macrolides, eg
efflux pumps, drug inactivation or alteration
INTRODUCTION
Among Campylobacter species, C. jejuni
and C. coli are the most common species as-
sociated with gastroenteritis worldwide with the
prevalence of C. jejuni generally being higher
than C. coli (Bodhidatta et al, 2002). Antimi-
crobial resistance in Campylobacter spp has
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of drug target site. Our study aim was to de-
termine the genetic background for macrolide
(both erythromycin and azithromycin) resis-
tance among clinical C. jejuni and C. coli iso-
lated from Thai children during 1991-2000 and
to determine other antimicrobial resistance




During 1991-2000, a total of 968 C. jejuni
and 200 C. coli isolates from diarrhea etiol-
ogy studies from different parts in Thailand
were identified by standard microbiological
procedures at the Armed Forces Research
Institute of Medical Sciences (AFRIMS),
Bangkok. Briefly, stool cultures were pro-
cessed by a modified filtration method (Steele
and McDermott, 1984). All C. jejuni and C. coli
were identified by biochemical tests and dif-
ferentiated by hippurate hydrolysis. Confirmed
C. jejuni and C. coli isolates were kept frozen
at -70ºC in glycerol medium for further char-
acterization.
Disk and minimum inhibitory concentration (MIC)
susceptibility testing
All 495 C. jejuni and 122 C. coli isolates
were tested as part of routine laboratory analy-
ses for antimicrobial susceptibility by disk dif-
fusion assay as described by Bauer et al  (1966)
with minor modifications. An 18-48 hours sub-
culture of C. jejuni and C. coli on sheep blood
agar plates, isolates were suspended in Mueller
Hinton broth (BD-Diagnostic Systems, Sparks,
MD, USA) to obtain a turbidity equivalent to a
1.0 McFarland standard, and inoculated onto
Mueller Hinton II agar supplemented with 5%
sheep blood. Isolates were tested for the fol-
lowing antimicrobials using disk diffusion (BD):
erythromycin (15 mg), azithromycin (15 mg),
nalidixic acid (30 mg) and ciprofloxacin (5 mg).
As no standardized interpretive criteria exist for
Campylobacter, the inhibition zones were in-
terpreted following the disks manufacturer’s
instructions. Campylobacter spp isolates found
resistant to both erythromycin and azithromycin
by disk diffusion tests were further tested for
MICs by the agar dilution method (National
Committee for Clinical Laboratory Standards,
2004a,b) to the following antimicrobials with
MICs ranges indicated in brackets: erythromy-
cin (0.2-32 µg/ml), azithromycin (0.25-32 µg/
ml), nalidixic acid (1-128 µg/ml), ciprofloxacin
(0.03-16 µg/ml), chloramphenicol (1-64 µg/ml),
gentamicin (0.25-32 µg/ml), streptomycin (1-
64 µg/ml) and tetracycline (0.5-32 µg/ml).
PCR and DNA sequencing
DNA templates were prepared by the
boiled culture method. PCR was conducted
using the universal primers of 23S rDNA (for-
ward primer 5´-GTA AAC GGC GGC CGT AAC
TA 3´ and reverse primer 5´-GAC CGA ACT
GTC TCA CGA CG-3´ ) as described previously
(Jensen and Aarestrup, 2001). The 699-bp
amplicons were separated and purified by
QIAquick PCR purification kit (Qiagen, CA,
USA).
An internal amplicon of the domain V of
the 23S rDNA of each isolate (12 C. jejuni and
23 C. coli that were all resistant to erythromy-
cin and azithromycin) were submitted for se-
quencing. Sequences were edited, aligned
and analysed using Sequencher program ver-
sion 4.6 (Gene Codes Corporation, Ann Ar-
bor, MI, USA). All 23S rDNA sequences were
compared with 23S rDNA sequences obtained
from GenBank (C. jejuni ATCC 700819 and
C. coli U0961) and from erythromycin and
azithromycin susceptible Campylobacter iso-
lates in this study (3 C. jejuni and 1 C. coli).
RESULTS
Among the 617 Campylobacter spp
tested (495 C. jejuni and 122 C. coli isolates),
resistance to both erythromycin and azithro-
mycin were detected in 12 C. jejuni and 23
C. coli isolates. As compared to erythromycin
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Antimicrobial drug MIC (µg/ml) No. of  resistant isolates/
(MIC range µg/ml) total isolates
Nalidixic (1-128) = 64 9/35
≥128 26/35
Ciprofloxacin (0.03-16) = 8 2/35
≥ 16 33/35
Tetracycline (0.5-32) = 32 1/35
≥ 32 32/35
Streptomycin (1-64) = 16 2/35
= 32 2/35
≥ 64 25/35
Gentamicin (0.25-32) > 32 3/35
Table 1
Minimum inhibitory concentration (MIC) of selected antimicrobials among 35 macrolide
resistant C. jejuni and C. coli isolates.
and azithromycin susceptible isolates, MICs
> 32 µg/ml for both erythromycin and azithro-
mycin was observed in all 35 isolates, while
all four susceptible isolates (3 C. jejuni : CJ-
558-1, CJ 1409 and SPH-2353-1) and one
C. coli (CJ-558) showed MICs ranging from
≤ 2-32 µg/ml and ≤ 0.25-2 µg/ml for erythro-
mycin and azithromycin, respectively. How-
ever, at the time of this study in 2004, there
were no MICs ranges for a control Campy-
lobacter strain with nalidixic acid, azithromycin,
streptomycin and chloramphenicol. Therefore,
the break points to these four antimicrobials
followed NCCLS standard interpretation of
gram-negative and gram-positive bacteria (Na-
tional Committee for Clinical Laboratory Stan-
dards, 2002a). MICs ranges for those isolates
tested with nalidixic acid (MIC ≥ 64 µg/ml),
ciprofloxacin (MIC ≥ 4 µg/ml), tetracycline (MIC
≥ 16 µg/ml) and streptomycin (MIC ≥16 µg/ml)
were considered as resistant. Among the eryth-
romycin and azithromycin resistant isolates
(Table 1), 100% (35 /35) showed resistance to
both nalidixic acid (MICs ≥ 64 µg/ml) and
ciprofloxacin (MICs ≥ 8-16 µg/ml). Moreover,
94% (33/35) and 83% (29/35) of these iso-
lates were also resistant to tetracycline (MICs
≥ 32 µg/ml) and streptomycin (MICs ≥ 16 µg/
ml). Resistance to gentamicin (MIC > 32 µg/
ml) was low at 8% (3/35) and resistance to
chloramphenicol was not detected. The mul-
tiple resistance patterns among C. jejuni and
C. coli are shown in Table 2. The most com-
mon multiple resistant phenotype was type A,
showing resistance to erythromycin, azithro-
mycin, nalidixic acid, ciprofloxacin, tetracycline
and streptomycin.
DNA sequences of 35 amplicons of 699
bp-size from the erythromycin and azithro-
mycin resistant Campylobacter isolates were
determined, analyzed and compared with
similar 23S rDNA nucleotide sequences of the
control strains C. coli U 09691, C. jejuni ATCC
700981 as well as of four erythromycin and
azithromycin susceptible C. jejuni and C. coli
isolates from this study. All macrolide-resis-
tant isolates, except one (SPH-1977-1)
showed a single point mutation of 23S rDNA
sequence at the position of 2230 created by
a base substitution of A to G compared to C.
coli U09691(number equivalent to 2059 in E.
coli J01695) from GenBank. A summary of the
23S rDNA mutations found is shown in Table
2. Three C. coli isolates (CJ-1732-1, CJ-1782-
1 and CJC 1761-8) showed an additional base
substitution at position of 2252 from C to T.
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Isolates (Year) Pathogen Serotype Resistance Base transition and position b
(Lior’s) phenotype
RVB-184-1 (1999) C. coli Un-typed A A2059G
RVB-203-1 (1999) C. coli Un-typed A A2059G
CJ-120-1 (1999) C. coli Un-typed B A2059G
CJ-190-1 (1996) C. coli Un-typed A A2059G
CJ-284-1 (1996) C. coli Un-typed A A2059G
CJ-1113-1 (1996) C. coli Un-typed A A2059G, A2279G, G2305A, T2307G, T2310G,
T2325G, A2326C, T2328A, C2354T, C2372T,
G2378A, C2388T, A2390G, G2393A
CJ-1172-1 (1997) C. coli Un-typed A A2059G
CJ-1456-2 (1997) C. coli Un-typed A A2059G
CJ-1524-3 (1997) C. coli Un-typed A A2059G
VC-949 (1995) C. coli Un-typed B A2059G
VC-348 (1994) C. coli Un-typed A A2059G
VC-336 (1994) C. coli 110 A A2059G
CJ-1782-1 (1997) C. coli 20 A A2059G, C2252T
CJ-1732-1 (1997) C. coli 20 A A2059G, C2252T
SPH-2353 (1996) C. coli 20 A A2059G
VC-1324 (1995) C. coli 20 C A2059G
RVB-128-1 (1995) C. coli 29 C A2059G
CJ-1566-1 (1997) C. coli 29 D A2059G
V-1068-1 (1995) C. coli 44 A A2059G
CJ-243-1 (1996) C. coli 45 A A2059G
CJC-1761-8 (1997) C. coli 55 B A2059G, C2252T, C2372T, G2378A, C2388T,
A2390G, G2393A
RV-0305D1 (1999) C. coli  8 A A2059G
CJ-516-6 (1996) C. coli  8 A A2059G
RV-0304 (1999) C. jejuni Un-typed A A2059G
RV-0323 (1999) C. jejuni Un-typed A A2059G
RVB-0064 (1999) C. jejuni Un-typed A A2059G
RVB-175-1 (1999) C. jejuni Un-typed A A2059G
CJ-1724-2 (1997) C. jejuni Un-typed B A2059G
SPH-1977-1 (1995) C. jejuni Un-typed A No mutation
CJ-874-1 (1996) C. jejuni Un-typed C A2059G
CJ-481-1 (1996) C. jejuni 19 C A2059G
V-863-1 (1995) C. jejuni 19 A A2059G
VC-114 (1993) C. jejuni 19 B A2059G
AX-0247 (1999) C. jejuni 28 D A2059G
CJ-1839-1(1997) C. jejuni   6 A A2059G
CJ-558-1a C. coli 44 NAL,CIP, TET, STR No mutation
CJ-558-1a C. jejuni 36 NAL, CIP, TET No mutation
CJ-1409 a C. jejuni Un-typed No resistance No mutation
SPH-2353-4a C. jejuni 11 No resistance No mutation
ATCC 700981 C. jejuni Unknown Not tested No mutation
Table 2
Multiple resistance phenotype and base transition of 23S rDNA of 23 C. jejuni and
12 C. coli isolates from Thailand.
A, resistance to erythromycin, azithromycin, nalidixic acid, ciprofloxacin, tetracycline, streptomycin
B, resistance to erythromycin, azithromycin, nalidixic acid, ciprofloxacin, tetracycline, streptomycin, gentamicin
C, resistance to erythromycin, azithromycin, nalidixic acid, ciprofloxacin, tetracycline
D, resistance to erythromycin, azithromycin, nalidixic acid, ciprofloxacin
NAL (nalidixic acid), CIP (ciprofloxacin), TET (tetracycline), STR (streptomycin)
a, Macrolide susceptible Campylobacter isolates used as controls
b, number of position equivalent to E. coli J01695
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Additionally, several more point mutations at
different positions were detected in two mac-
rolide resistant C. coli isolates (CJ-1113-1 and
CJC 1761-8).
DISCUSSION
In this study, a possible genetic basis of
erythromycin and azithromycin resistance
among C. jejuni and C. coli isolates was by a
common point mutation causing a substitu-
tion of base A to G at the equivalent position
of 2230 compared to 23S rDNA of C. coli
(equivalent to position 2059 of E. coli J01695)
(Jensen and Aarestrup, 2001; Vester and
Douthwaite, 2001). This mutation causes an
alteration of the drug binding target site of
domain V in the 23S rRNA. None of the C.
jejuni and C. coli isolates had mutations at
position 2058 compared to E. coli J01965 as
reported previously (Vester and Douthwaite,
2001). Additional sequence mutations in 23S
rDNA were detected in four C. coli isolates
(CJ-1113-1, CJ 1732-1, CJ 1782-1 and CJC-
1761-8) in Table 2. In this study, C. jejuni iso-
lates were less f requent ly res istant to
macrolides than C. coli (2.4% and 17% resis-
tance, respectively). High prevalence of mac-
rolide resistance among C. coli isolates from
swine has been cited in a previous publica-
tion and thus the use of macrolides in animal
production may lead to the emergence of
macrolide-resistant isolates in human (Gibreel
et al, 2005). In this study, the first multiple re-
sistant (resistant phenotype B, Table 2) was
observed from C. jejuni (VC-114) isolated in
1993. In addition, there was no association
between multiple resistant isolates and Lior
serotypes. The finding of mutation of 23S rRNA
in our Campylobacter isolates does not rule out
other possible mechanisms involved in mac-
rolide resistance (Gibreel et al, 2005). MIC test-
ing with both erythromycin and azithromycin
was not performed at the concentration >32
µg/ml to observe whether a further increase of
MICs might relate to additional point mutations
in the two Campylobacter isolates CJ-1113-1
and CJC-1761-8.
In summary, point mutation of 23S rRNA
similar to those previously reported was as-
sociated with reduced susceptibi l i ty to
macrolides in clinical C. jejuni and C. coli iso-
lated in Thailand. The high occurrence of mul-
tiple resistances among macrolide-resistant
isolates is of concern as such strains will not
respond to standard therapeutic treatment of
campylobacteriosis and their spread should
therefore be monitored closely. Although
prevalence of macrolide resistance among
human Campylobacter isolates from Thailand
has not reached the level of fluoroquinolone
resistance in Thailand and elsewhere (Hoge
et al, 1998), the switch to antimicrobial usage
could have selected for the multiple resistance
seen in the tested human Campylobacter,
leaving very few available treatment options.
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